A proportion of extraskeletal myxoid chondrosarcomas (EMC) have been shown to have a characteristic translocation t(9;22)(q22;q12) involving the EWS gene at 22q12 and the CHN orphan nuclear receptor gene at 9q22. This translocation appears to be largely speci®c for EMC, but has not been detected in all such tumours. We report here a case of EMC with a t(9;17)(q22;q11.2) as the sole chromosome abnormality. We have determined that the translocation results in the fusion of the entire coding region of CHN to the N-terminal transactivation domain of RBP56/hTAF II 68. This is the ®rst report of a translocation involving RBP56/hTAF II 68, a protein with sequence homology to both EWS and TLS/FUS. The involvement of RBP56/hTAF II 68 may explain some unusual features of the tumour.
Although recurrent chromosomal abnormalities are frequent in haematological malignancies, they are relatively uncommon in solid tumours. An exception to this is in the case of some sarcomas where a number of recurrent changes have been identi®ed. The best characterized chromosomal rearrangements occur in Ewing's and related tumours, which have translocations which fuse the N-terminal transactivation domain of the EWS gene to the DNA-binding domain of one of a number of transcription factors. All these gene fusions have the consequence that the non-transforming transcription factor is converted into a transforming protein with novel and potent transactivation properties endowed by the N-terminal portion of EWS (for review see Ladanyi, 1995) . EWS is a member of a family of genes including TLS/FUS and RBP56/hTAF II 68, each encoding a protein which associates with components of the transcription machinery, with the latter two proteins being involved in elongation as well as initiation (Bertolotti et al., 1996 (Bertolotti et al., , 1998 . The C-terminal domains of EWS and hTAF II 68 have been shown to be essential for interaction with other TBP-associated factors (TAF II s) within the TFIID multiprotein complex (Bertolotti et al., 1998) . As the C-terminal domain of EWS is missing in all the fusion proteins involving this gene characterized to date, the interaction with TFIID would be seriously compromised.
The identi®ed fusion partners for EWS have been extended to include the entire coding region of either CHOP in myxoid liposarcomas (t(12;22)(q13;q12), Panagopoulos et al., 1996) or CHN in extraskeletal myxoid chondrosarcomas (t(9;22)(q22;q12), Labelle et al., 1995; Clark et al., 1996; Brody et al., 1997; Antonescu et al., 1998) . Both these genes encode proteins which have DNA-binding domains. One other member of the EWS gene family, TLS/FUS, has also been implicated in human tumours by virtue of recurrent translocations. TLS/FUS-CHOP fusions has been identi®ed in a subset of myxoid liposarcomas (t(12;16)(q13;p11), Crozat et al., 1993; Rabbitts et al., 1993) , and TLS/FUS-ERG fusions have been found in acute myeloid leukaemias (t(16;21)(p11;q22), Ichikawa et al., 1994) .
To date, there have been no reports of involvement of a third member of this gene family, RBP56/ hTAF II 68, in any human malignancy, although it could be predicted from its structure that it would be an appropriate candidate. We present here the ®rst report of such an involvement in an extraskeletal myxoid chondrosarcoma (EMC) with neuroendocrine features. The EMC arose in the right buttock of a 54-year male. Histology showed a tumour with abundant myxoid, Alcian blue-positive stroma in which the tumour cells formed cords and clusters. Evidence for cartilagenous dierentiation was as follows: the presence of intracellular glycogen, immunopositivity for S100 protein, an Alcian blue critical electrolyte concentration of 0.5 ± 0.6 molar (Scott and Dorling, 1965) , stromal metachromasia with toluidine blue and resistance of stromal Alcian blue staining to hyaluronidase digestion. The tumour cells contained brightly eosinophilic granules and these were shown to be neuroendocrine in type by a positive Grimelius stain, positive staining for chromogranin A and synaptophysin and ultrastructural demonstration of typical dense core granules. The detailed pathological ®ndings will be published elsewhere (Harris et al. manuscript in preparation).
All cells analysed from chromosome preparations showed a balanced reciprocal translocation between the long arms of chromosomes 9 and 17, with breakpoints at bands q22 and q11.2 respectively (Figure 1 ). The rearrangement of band 9q22 is a crucial event in the development of EMC, and implicates the CHN gene which is normally translocated adjacent to the EWS gene on chromosome band 22q12 (Labelle et al., 1995; Clark et al., 1996; Brody et al., 1997; Antonescu et al., 1998) . There is one other report of a translocation in EMC involving 9q22 and 17q11.2, but the karyotype reported was very complex, and no molecular analysis was reported (Mark-Vendel et al., 1991) .
Investigation of candidate genes mapping to chromosome band 17q11.2 showed that RBP56/ hTAF II 68 mapped within this region (Morohoshi et al., 1996) . We therefore designed PCR primers with which to amplify reverse-transcribed RNA isolated from the tumour. These primers were designed on the basis of known fusions within CHN, and by comparison with the position of breakpoints in the EWS gene. Two main types of EWS/CHN fusion have been identi®ed in EMC; type 1 in which the entire open reading frame of CHN is fused to exon 12 of EWS, and type 2 in which the fusion has occurred at position 7176 of CHN and exon 7 of EWS. The CHN reverse primers were as reported (Brody et al., 1997) , and three forward RBP56/hTAF II 68 primers were designed to represent equivalent regions to those characterized in the EWS/CHN fusions. The positions of these primers are indicated in Figure 2a .
RT ± PCR products were obtained using primer combinations of RBP56C and B, and CHNREVA and C. Sequence analysis of the products con®rmed the Brody et al. (1997) . The primers for RBP56/hTAF II 68 are as follows: RBP56A ± 5'-GGGGAGGCAACAGTGTCATTTG-3'; RBP56B ± 5'-CAGCAGTCAGGCTATGATCAAC-3'; RBP56C ± 5'-CTATGGTCAA-CAAGATTCATATGAC-3'. RNA was isolated from a snap-frozen tumour biopsy using a micro-Fast Track 2.0 mRNA isolation system (InVitrogen) and was ampli®ed using pairs of primers for 30 cycles (948C 1 min, 608C 1 min, 728C 1 min) after an initial denaturation at 978C for 5 min. The PCR products were sequenced directly by cycle sequencing using either the speci®c forward or reverse primers, and were analysed using an ABI model 377 automated sequencer. (b) Partial sequence of the fusion protein. The RBP56/hTAF II 68 DNA and protein sequences are shown in plain text, the CHN DNA sequence is italicized and the amino acid sequence is shown in bold. This sequence has been assigned the GenBank accession number AF162670 Figure 1 Partial karyotype of the t(9;17)(q22;q11.2). Cytogenetic preparations were obtained by maceration of a small piece of tumour (approx 1 cm 3 ) and digestion with collagenase (Sigma Type II, 1500 U/ml) for 1 h at 378C. Cells were cultured in Ham's F10 medium (Gibco) for 19 days, and were harvested after 2.5 h incubation in Colcemid (Gibco, 0.2 mg/ml ®nal concentration). Metaphase chromosomes were prepared and G-banded (GTL) using standard procedures. The normal chromosomes and ideograms are on the left of each pair. The arrows indicate the positions of the breakpoints on chromosomes 9 and 17 hTAF II 68/CHN fusion in EMC C Attwooll et al involvement of RBP56/hTAF II 68 and CHN (Figure 2b) , and furthermore indicated that the translocation had occurred between intron 6 of RBP56/hTAF II 68 and intron 2 of CHN (details of the gene structure taken from Ohkura et al., 1996; Morohoshi et al., 1998 (Labelle et al., 1995; Brody et al., 1997; Antonescu et al., 1998) . There appear to be no histopathological dierences between those tumours with the EWS-CHN fusion, and those in which such a change could not be detected (Brody et al., 1997) . It remains possible that these two genes are still involved in the negative tumours described by other groups (for example via a cryptic translocation). It is however currently unclear what proportion of the remainder have translocations involving dierent combinations of genes such as that reported here. In the present study we have characterized a translocation between RBP56/hTAF II 68 on chromosome band 17q112 and CHN (9q22) in a case of EMC. This tumour showed a remarkable feature which is not typical of EMC, notably, neuroendocrine dierentiation (Harris et al. manuscript in preparation). This phenomenon has been reported previously only once (Chhieng et al., 1998) . There is one other report in the literature of a case of EMC with a complex karyotype including a three-way translocation involving chromosome bands 9q22, 17q11.2 and 15q22. It is possible that this complex rearrangement resulted in a RBP56/hTAF II 68-CHN fusion as described here, but no details of the pathological or clinical features were given, and no molecular analysis has been recorded.
Given the close homology between EWS, TLS/FUS and RBP56/hTAF II 68 it is perhaps not surprising that the latter gene has now been identi®ed in a case of EMC. It would be of great interest to examine a range of tumours in which typical translocations/fusions have not been detected for the involvement of RBP56/ hTAF II 68 to determine the frequency with which this gene is implicated in the development of a variety of sarcomas.
It is currently unclear whether the speci®c fusion reported here involving RBP56/hTAF II 68 is associated with the marked neuroendocrine features of this tumour. However of the seven cases of EMC with neuroendocrine dierentiation reported by Chhieng et al. (1998) , one case was shown to have an EWS-CHN fusion. Detailed in vitro studies would be required to resolve this question.
